methyl 5-(chlorosulfonyl)-3-methylfuran-2-carboxylate | 1253225-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: methyl 5-(chlorosulfonyl)-3-methylfuran-2-carboxylate
• 英文别名: methyl 5-chlorosulfonyl-3-methylfuran-2-carboxylate
• CAS: 1253225-69-2
• 化学式: C₇H₇ClO₅S
• 分子量: 238.649
• InChiKey: HEXWEIMKHZBKHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  82
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 5-(chlorosulfonyl)-3-methylfuran-2-carboxylate 在 氨 作用下， 以 甲醇 为溶剂， 以4 g的产率得到methyl 3-methyl-5-sulfamoylfuran-2-carboxylate
  参考文献：
  名称：

  [EN] NLRP3 INHIBITORS
  [FR] INHIBITEURS DE NLRP3

  摘要：

  Disclosed herein are small molecule compounds that are capable of inhibiting NLRP3 family proteins and NLRP3 inflammasome function in various disease settings. The disease is characterized by a disease progression pathology that comprises the activity of NLRP3 inflammasome. Disclosed herein also include pharmaceutical compositions comprising a therapeutically effective amount of the NLRP3 inhibitor compound, the use and preparation thereof.

  公开号：

  WO2024010772A1
• 作为产物：
  描述：

  在 五氯化磷 作用下， 以 氯仿 为溶剂， 生成 methyl 5-(chlorosulfonyl)-3-methylfuran-2-carboxylate
  参考文献：
  名称：

  [EN] NLRP3 INHIBITORS
  [FR] INHIBITEURS DE NLRP3

  摘要：

  Disclosed herein are small molecule compounds that are capable of inhibiting NLRP3 family proteins and NLRP3 inflammasome function in various disease settings. The disease is characterized by a disease progression pathology that comprises the activity of NLRP3 inflammasome. Disclosed herein also include pharmaceutical compositions comprising a therapeutically effective amount of the NLRP3 inhibitor compound, the use and preparation thereof.

  公开号：

  WO2024010772A1

文献信息

• [EN] NLRP3 INHIBITORS<br/>[FR] INHIBITEURS DE NLRP3
  申请人：[en]KODIAK SCIENCES INC.

  公开号：WO2024010772A1

  公开（公告）日：2024-01-11

  Disclosed herein are small molecule compounds that are capable of inhibiting NLRP3 family proteins and NLRP3 inflammasome function in various disease settings. The disease is characterized by a disease progression pathology that comprises the activity of NLRP3 inflammasome. Disclosed herein also include pharmaceutical compositions comprising a therapeutically effective amount of the NLRP3 inhibitor compound, the use and preparation thereof.